NASDAQ:RGEN

Repligen Stock Forecast, Price & News

$206.61
+0.51 (+0.25 %)
(As of 04/12/2021 09:31 AM ET)
Add
Compare
Today's Range
$205.25
Now: $206.61
$206.61
50-Day Range
$180.37
MA: $199.10
$221.73
52-Week Range
$95.91
Now: $206.61
$228.84
Volume212 shs
Average Volume411,628 shs
Market Capitalization$11.32 billion
P/E Ratio251.96
Dividend YieldN/A
Beta0.94
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Repligen logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGEN
CUSIP75991610
Phone(781) 250-0111
Employees1,128
Year Founded1981

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$270.24 million
Cash Flow$1.40 per share
Book Value$20.36 per share

Profitability

Net Income$21.41 million

Miscellaneous

Market Cap$11.32 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

Headlines

Reviewing Inhibrx (NASDAQ:INBX) and Repligen (NASDAQ:RGEN)
April 10, 2021 |  americanbankingnews.com
Is RGEN Stock A Buy or Sell? - Yahoo Finance
April 7, 2021 |  finance.yahoo.com
Is RGEN Stock A Buy or Sell?
April 7, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

474th out of 2,011 stocks

Biological Products, Except Diagnostic Industry

69th out of 176 stocks

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$206.61
+0.51 (+0.25 %)
(As of 04/12/2021 09:31 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Repligen (NASDAQ:RGEN) Frequently Asked Questions

Is Repligen a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Repligen stock.
View analyst ratings for Repligen
or view top-rated stocks.

What stocks does MarketBeat like better than Repligen?

Wall Street analysts have given Repligen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Repligen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Repligen's next earnings date?

Repligen is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Repligen
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) posted its earnings results on Tuesday, February, 23rd. The biotechnology company reported $0.52 EPS for the quarter, topping the Zacks' consensus estimate of $0.31 by $0.21. The biotechnology company earned $108.65 million during the quarter, compared to the consensus estimate of $93.89 million. Repligen had a net margin of 13.40% and a trailing twelve-month return on equity of 6.58%.
View Repligen's earnings history
.

How has Repligen's stock price been impacted by COVID-19 (Coronavirus)?

Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGEN shares have increased by 127.0% and is now trading at $206.61.
View which stocks have been most impacted by COVID-19
.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY21 earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of $1.86-$1.94 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.65. The company issued revenue guidance of $500-$525 million, compared to the consensus revenue estimate of $459.50 million.

What price target have analysts set for RGEN?

5 Wall Street analysts have issued 12-month target prices for Repligen's shares. Their forecasts range from $150.00 to $251.00. On average, they expect Repligen's stock price to reach $219.00 in the next year. This suggests a possible upside of 6.0% from the stock's current price.
View analysts' price targets for Repligen
or view top-rated stocks among Wall Street analysts.

Who are Repligen's key executives?

Repligen's management team includes the following people:
  • Tony J. Hunt, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Jim Bylund, Senior Vice President-Global Operations & IT (LinkedIn Profile)
  • Jon K. Snodgres, Chief Financial Officer (LinkedIn Profile)
  • Ralf Kuriyel, Senior Vice President-Research & Development
  • Squire Servance, Secretary, Senior VP & General Counsel

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among Repligen's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Repligen's key competitors?

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), The Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by a number of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.02%) and Pacer Advisors Inc. (0.01%). Company insiders that own Repligen stock include Anthony Hunt, Christine Gebski, Glenn L Md Cooper, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends for Repligen
.

Which institutional investors are buying Repligen stock?

RGEN stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Pacer Advisors Inc..
View insider buying and selling activity for Repligen
or or view top insider-buying stocks.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $206.61.

How much money does Repligen make?

Repligen has a market capitalization of $11.32 billion and generates $270.24 million in revenue each year. The biotechnology company earns $21.41 million in net income (profit) each year or $1.07 on an earnings per share basis.

How many employees does Repligen have?

Repligen employs 1,128 workers across the globe.

Does Repligen have any subsidiaries?

The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.

When was Repligen founded?

Repligen was founded in 1981.

What is Repligen's official website?

The official website for Repligen is www.repligen.com.

Where are Repligen's headquarters?

Repligen is headquartered at 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at (781) 250-0111 or via email at [email protected]


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.